Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer

✍ Scribed by Junzo Kigawa; Yukihisa Minagawa; Yasunobu Kanamori; Hiroaki Itamochi; Xiusi Cheng; Makoto Okada; Tetsuro Oishi; Naoki Terakawa

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 162 KB
• Volume: 82
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19980215)82:4<697::aid-cncr12>3.0.co;2-t

✦ Synopsis

in tumor samples was determined by immunohistochemical staining and Western blot analysis. GSH concentration was measured by an enzymatic assay. Department of Obstetrics and Gynecology, Tot-

RESULTS.

The response rate was 38.4%. The estimated 3-year survival rate for tori University School of Medicine, Yonago, Jathe responders (66.7%) significantly exceeded that for the nonresponders (9.1%). pan.

Expression of GST-p by immunohistochemical staining was more frequently observed in nonresponders (2 of 10 responders vs. 11 of 16 nonresponders). Western blot analysis detected GST-p in all cases. There was no significant difference in the relative density values of the GST-p Western blot analysis between the two groups. The mean value of GSH concentration in nonresponders was significantly higher than in responders (18.4 { 9.7 vs. 7.5 { 8.2 mg/mg protein). GSH concentration was below the cutoff point (10.3 mg/mg protein) in all responders except one.

CONCLUSIONS.

Second-line chemotherapy consisting of etoposide and cisplatin is effective in the treatment of relapsed epithelial ovarian cancer. In addition, tumor concentration of GSH may be a useful predictor of the response to this therapy.